A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Neurocrine (NBIX – Research Report), with a price ...
Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...
Zacks.com on MSN17h
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback